Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRUIN MCL-321: Pirtobrutinib vs covalent BTK inhibitors in previously treated mantle cell lymphoma
jRCT2021210026Phase 3Active, not recruiting
- Sponsor
- Loxo Oncology
- Start
- Nov 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of pirtobrutinib in mantle cell lymphoma (MCL) (2 arms), sponsored by Loxo Oncology. Primary endpoint: Progression-free survival. Started Nov 2021; status: active, not recruiting.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on jRCT2021210026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210026.